{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:31:54Z","timestamp":1793338314991,"version":"4.5.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T00:00:00Z","timestamp":1710374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T00:00:00Z","timestamp":1710374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-024-01033-7","type":"journal-article","created":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T07:47:36Z","timestamp":1710402456000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Age-specific survival in acute myeloid leukemia in the Nordic countries through a half century"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2769-3316","authenticated-orcid":false,"given":"Kari","family":"Hemminki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frantisek","family":"Zitricky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asta","family":"F\u00f6rsti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Kontro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9358-9704","authenticated-orcid":false,"given":"Bjorn T.","family":"Gjertsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0996-1812","authenticated-orcid":false,"given":"Marianne Tang","family":"Severinsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7911-7265","authenticated-orcid":false,"given":"Gunnar","family":"Juliusson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,14]]},"reference":[{"key":"1033_CR1","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1038\/s41375-023-01852-w","volume":"37","author":"K Hemminki","year":"2023","unstructured":"Hemminki K, Hemminki J, F\u00f6rsti A, Sud A. Survival in hematological malignancies in the Nordic countries through a half century with correlation to treatment. Leukemia. 2023;37:854\u201363.","journal-title":"Leukemia"},{"key":"1033_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0323-4","volume":"10","author":"D Pulte","year":"2020","unstructured":"Pulte D, Jansen L, Brenner H. Changes in long term survival after diagnosis with common hematologic malignancies in the early 21st century. Blood Cancer J. 2020;10:56.","journal-title":"Blood Cancer J"},{"key":"1033_CR3","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"1033_CR4","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","volume":"401","author":"CD DiNardo","year":"2023","unstructured":"DiNardo CD, Erba HP, Freeman SD, Wei AH. Acute myeloid leukaemia. Lancet. 2023;401:2073\u201386.","journal-title":"Lancet"},{"key":"1033_CR5","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/s41375-021-01503-y","volume":"36","author":"ZLR Kaplan","year":"2022","unstructured":"Kaplan ZLR, van Leeuwen N, Posthuma EFM, Visser O, Huls G, van de Loosdrecht AA, et al. Improved relative survival in older patients with acute myeloid leukemia over a 30-year period in the Netherlands: a long haul is needed to change nothing into something. Leukemia. 2022;36:596\u20138.","journal-title":"Leukemia"},{"key":"1033_CR6","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1080\/10428194.2021.1893315","volume":"62","author":"TMH Naur","year":"2021","unstructured":"Naur TMH, Jakobsen LH, Roug AS, El-Galaly TC, Marcher CW, N\u00f8rgaard JM, et al. Treatment intensity and survival trends among real-world elderly AML patients diagnosed in the period 2001-2016: a Danish nationwide cohort study. Leuk Lymphoma. 2021;62:2014\u20137.","journal-title":"Leuk Lymphoma"},{"key":"1033_CR7","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","volume":"113","author":"G Juliusson","year":"2009","unstructured":"Juliusson G, Antunovic P, Derolf A, Lehmann S, M\u00f6llg\u00e5rd L, Stockelberg D, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009;113:4179\u201387.","journal-title":"Blood"},{"key":"1033_CR8","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1182\/blood.2019001728","volume":"134","author":"G Juliusson","year":"2019","unstructured":"Juliusson G, Hagberg O, Lazarevic VL, \u00d6lander E, Antunovic P, Cammenga J, et al. Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period. Blood. 2019;134:1558\u201361.","journal-title":"Blood"},{"key":"1033_CR9","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/ajh.27138","volume":"99","author":"N Gangat","year":"2024","unstructured":"Gangat N, Karrar O, Iftikhar M, McCullough K, Johnson IM, Abdelmagid M, et al. Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients. Am J Hematol. 2024;99:193\u2013202.","journal-title":"Am J Hematol"},{"key":"1033_CR10","unstructured":"Lar\u00f8nningen SAG, Bray F, Engholm G, Ervik M, Gu\u00f0mundsd\u00f3ttir EM, Gulbrandsen J, et al. NORDCAN: cancer incidence, mortality, prevalence and survival in the Nordic countries, Version 9.3 (02.10.2023). 2023."},{"key":"1033_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00728-z","volume":"12","author":"K Hemminki","year":"2022","unstructured":"Hemminki K, Hemminki J, F\u00f6rsti A, Sud A. Survival trends in hematological malignancies in the Nordic countries through 50 years. Blood Cancer J. 2022;12:150.","journal-title":"Blood Cancer J"},{"key":"1033_CR12","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1111\/bjh.17213","volume":"193","author":"L Hjort Jakobsen","year":"2021","unstructured":"Hjort Jakobsen L, Stidsholt Roug A, Kiesbye \u00d8vlisen A, Werenberg Marcher C, Beier Ommen H, Theilgaard-M\u00f6nch K, et al. Temporal changes in survival among adult patients with acute myeloid leukaemia in the period 2000-2016: a Danish population-based study. Br J Haematol. 2021;193:482\u20137.","journal-title":"Br J Haematol"},{"key":"1033_CR13","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/bjh.19165","volume":"204","author":"BT Gjertsen","year":"2024","unstructured":"Gjertsen BT. How to discover the exceptional venetoclax responders in AML\/MDS? Br J Haematol. 2024;204:14\u20135.","journal-title":"Br J Haematol"},{"key":"1033_CR14","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/bjh.16265","volume":"188","author":"\u00c5 Derolf","year":"2020","unstructured":"Derolf \u00c5, Juliusson G, Benson L, Fl\u00f8isand Y, Lazarevic V, Antunovic P, et al. Decreasing early mortality in acute myeloid leukaemia in Sweden 1997-2014: improving performance status is a major contributing factor. Br J Haematol. 2020;188:187\u201391.","journal-title":"Br J Haematol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01033-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01033-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01033-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T07:47:47Z","timestamp":1710402467000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01033-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,14]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1033"],"URL":"https:\/\/doi.org\/10.1038\/s41408-024-01033-7","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,14]]},"assertion":[{"value":"25 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Aggregated data from a publicly accessible database were used posing no ethical issues.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"MK reports personal fees from Astellas Pharma, AbbVie, Bristol-Myers Squibb, Faron, Jazz Pharmaceuticals, Novartis and Pfizer and research funding from AbbVie. BTG reports Stock and Other Ownership Interests: Kinn Therapeutics AS, Alden Cancer Therapy AS, H\u00e0 Biotech AS. Consulting or Advisory Role: Abbvie, Astellas Pharma, AstraZeneca AS, BerGenBio, Coegin Pharma, GreinDX, Immedica Pharma, Incyte, Laboratories Delbert, MSD (Norge) AS, Novartis, Otsuka. Speakers\u2019 Bureau Company: Pfizer, Sanofi Genzyme, Oslo Cancer Cluster, Novartis. GJ reports advisory board attendance and lecturing for AbbVie, Astellas, and Servier, and research collaboration with Jazz Pharma and Novartis. The other authors declare no conflict.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"44"}}